Boya Immunoglobulin Linked To Patient Deaths
This article was originally published in PharmAsia News
Following investigation of the six deaths attributed to lethal immunoglobulin from Jiangxi Boya Bio-Pharmaceutical, China's State FDA announced that the National Institute for the Control of Pharmaceutical and Biological Products has confirmed that the samples identified were directly linked to the patients who died. According to results of tests conducted, the drugs in question are confined to batch 20070514, and relevant authorities are examining the exact cause of the problem. The batch has been traced and is under effective control nationwide. SFDA revealed that last year, 547,000 adverse drug reports were received, 48.1 percent more than 2006. The rising incidence warrants greater attention for the welfare of affected consumers. (Click here for more - Chinese Language)
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.